-
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial SubanalysisJurrienM Berg, A de Veer, the RE-DUAL PCI Steering Committee and Investigators et al. -
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trialFeres F, Costa RA, OPTIMIZE Trial Investigators.
-
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art ReviewD Capodanno, K Huber, R Mehran et al.
-
ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy JACC Guideline Comparison: JACC State-of-the-Art ReviewD Capodanno, F Alfonso, GN Levine et al.
-
Genotyping to Guide Clopidogrel Treatment: An In-Depth Analysis of the TAILOR-PCI TrialNaveen L. Pereira, MBBS, FACC
-
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary InterventionD Sibbing, D Aradi, D Alexopoulos et al.
-
P2Y12 Inhibitor Monotherapy with Clopidogrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary InterventionPW Chen, WH Feng, MY Ho et al.
-
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-AnalysisM Valgimigli , R Mehran, SIDNEY Collaboration et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
